Research programme: immunological disorders therapeutics - Evotec/UCB

Drug Profile

Research programme: immunological disorders therapeutics - Evotec/UCB

Latest Information Update: 07 Nov 2013

Price : $50

At a glance

  • Originator Evotec AG; UCB
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Immunological disorders

Most Recent Events

  • 28 Oct 2013 Evotec achieves first milestones in the collaboration with UCB in the field of immunology
  • 05 Oct 2011 Early research in Immunological disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top